Ap­pili lands DOD mon­ey for bioter­ror­ism vac­cine; Goldfinch touts new PhII da­ta

The US De­part­ment of De­fense has se­lect­ed a No­va Scot­ian bio­phar­ma for a $10 mil­lion grant to ad­vance the pro­duc­tion of its biode­fense vac­cine ATI-1701.

Ap­pili Ther­a­peu­tics is pro­duc­ing a vac­cine to pre­vent the in­fec­tion of Fran­cisel­la tu­laren­sis, a top-pri­or­i­ty bio­threat and causative agent of tu­laremia. Fran­cisel­la tu­laren­sis, a Cat­e­go­ry A pathogen, has the abil­i­ty to cause lethal pneu­mo­nia and sys­temic in­fec­tion. An aerosolized form of the agent can be more in­fec­tive than an­thrax, the com­pa­ny said in a re­lease, and is con­sid­ered to have the po­ten­tial for a bioter­ror­ism at­tack.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER